Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (172)	11/2/2006 7:23:11 PM
From: david nordic	Respond to of 507

-- Total revenue for 2007 in the range of $210 to $250 million, including Exubera revenue of $110 to $130 million, with most of the estimated Exubera revenue based on estimated manufacturing sales of Exubera to Pfizer. Manufacturing Sales Only in 07??? 24/7 is approx. 40M /quarter. (This will add to Q4. 56M revenue range.) Projected total 2006 @ 203M revenue. With no Exubera royalties, is launch being push out? Is this due to the lawsuit or is this something else? I do not understand this. I guess we wait for PFE conference call in Nov. MICERA has problems. FDA questions and Amgn lawsuit pending.